SCHEMBL792496

SCHEMBL792496

CC(=O)c1ccc2c(C)c3n(c2c1)CCC3

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.41
MAPK1 P28482 1/20 0.41
APOBEC3A P31941 1/20 0.39
APOBEC3G Q9HC16 1/20 0.39
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
TP53 P04637 2/20 0.37
ALDH1A1 P00352 3/20 0.37
ALOX15 P16050 1/20 0.37
POLB P06746 4/20 0.37
THRB P10828 1/20 0.37
ALOX5 P09917 1/20 0.36
FABP4 P15090 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
SIGMAR1 Q99720 1/20 0.36
MAPT P10636 2/20 0.36
HPGD P15428 1/20 0.36
KDM4E B2RXH2 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL792527 0.96 ALDH1A1 (0.41) GAAMAPK1APOBEC3AAPOBEC3GHTR2A
SCHEMBL792524 0.90 FABP4 (0.45) GAAMAPK1HTR2AHTR2CALDH1A1
SCHEMBL792516 0.88 HTR7 (0.34) GAAMAPK1APOBEC3AAPOBEC3GTP53
SCHEMBL14572851 0.84 HTR2A (0.37) HTR2AHTR2CTP53ALDH1A1ALOX5
SCHEMBL792539 0.80 DRD3 (0.41) HTR2AHTR2CALDH1A1SIGMAR1MAPT
SCHEMBL792525 0.77 GFER (0.41) HTR2AHTR2CALDH1A1POLBALOX5
SCHEMBL792128 0.76 SIGMAR1 (0.32) APOBEC3AAPOBEC3GTP53ALDH1A1POLB
SCHEMBL792588 0.72 ALDH1A1 (0.42) HTR2AHTR2CALDH1A1FABP4SIGMAR1
SCHEMBL792066 0.71 MTNR1A (0.47) MAPK1MAPTKDM4ENPC1RAB9A
SCHEMBL26482560 0.69 TP53 (0.51) APOBEC3AAPOBEC3GTP53ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120070409-A1 TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR JAPAN TOBACCO INC. (JP) 2012-03-22 US disclosed
US-7977331-B1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2011-07-12 US disclosed
US-20070049593-A1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049593-A1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor POLI, TERT, ZC3HAV1 GAA 374/4885MAPK1 1154/4885APOBEC3A 2977/4885
US-20120070409-A1 TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR POLI, TERT, ZC3HAV1 GAA 374/4885MAPK1 1154/4885APOBEC3A 2977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.